Although our study preliminarily demonstrated that GGH repressed glycolysis, which has been considered to be driven by KRAS mutations in malignant tumors (51, 52), the mechanism by which GGH exerts its impact on tumor immune cell infiltration or the anti-tumor immune response vie the regulation of metabolic reactions or other crucial gene expression requires further exploration. The gene discussed is KRAS; the disease is neoplasm.